NeuroPace, Inc. (NPCE): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
NPCE Stock Price Chart Interactive Chart >
NPCE Price/Volume Stats
|Current price||$23.78||52-week high||$27.38|
|Prev. close||$24.07||52-week low||$18.24|
|Day high||$24.76||Avg. volume||155,880|
|50-day MA||$0.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||577.64M|
NeuroPace, Inc. (NPCE) Company Bio
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Latest News Stream
|Loading, please wait...|
NPCE Latest Social Stream
View Full NPCE Social Stream
Latest NPCE News From Around the Web
Below are the latest news stories about NeuroPace Inc that investors may wish to consider to help them evaluate NPCE as an investment opportunity.
NeuroPace, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the closing of its initial public offering of 6,900,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 900,000 additional shares of common stock, at the initial public offering price of $17.00 per share. The gross proceeds to NeuroPace, before deducting underwriting discounts and commissions and offering expenses, were approximately $117.3 million. NeuroPace’s common stock began trading on the Nasdaq Global Select Market on April 22, 2021 under the ticker symbol “NPCE.” J.P. Morgan and Morga...
Knowbe4 jumped nearly 51% in its market debut, while NeuroPace was up nearly 47% and Zymergen rose more than 21%.
MOUNTAIN VIEW, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17.00 per share. All shares of common stock are being offered by NeuroPace for total gross proceeds of $102 million, before deducting underwriting discounts and commissions and offering expenses. In addition, NeuroPace has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. NeuroPace’s common stock is ...
NPCE Price Returns